MMP1 and systemic sclerosis: Considering our results that showed salirasib can inhibit pro‐fibrotic mediators and myofibroblast differentiation which can result in the prevention of fibrosis, and up‐regulate MMP1 which can lead to the degradation of deposited ECM, it seems that salirasib has the potential to be a new curative strategy for SSc.